Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The impact of disease heterogeneity on treatment decisions in MDS

Eric Solary • 5 May 2023
MDS 2023
Myelodysplastic Syndromes

Eric Solary, MD, Gustave Roussy Institute, Paris, France, comments on the heterogeneity of myelodysplastic syndromes (MDS) in terms of both disease staging and molecular mechanisms, highlighting how disease heterogeneity influences treatment decisions. This interview was recorded at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Solary

1:09
Selecting patients with CMML for alloSCT
Eric Solary • 5 May 2023
0:51
Similarities between the WHO and ICC classifications for MDS & the need to create a unified approach
Eric Solary • 5 May 2023
2:03
The need to identify new treatment strategies in CMML & the potential of targeting inflammation
Eric Solary • 5 May 2023
0:55
Investigating the interactions between mesenchymal stromal cells in the bone marrow & leukemic cells
Eric Solary • 5 May 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals